No Data
No Data
No Data
Orchard Therapeutics Announces Launch Plans For Lenmeldy - Quick Facts
Orchard Therapeutics Receives FDA Approval of Lenmeldy (Atidarsagene Autotemcel), the Only Therapy for Eligible Children With Early-onset Metachromatic Leukodystrophy in the U.S.
Orchard Therapeutics today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).
ORI Capital Raises $260 Million for Second Life Sciences Fund
- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients
Express News | Orchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (Atidarsagene Autotemcel) Approved For The Treatment Of Early-onset Metachromatic Leukodystrophy (MLD)
No Data
SpyderCall : Good stuff. As usual.